Invasive Ductal Carcinoma Therapeutics Global Market Report 2025

The invasive ductal carcinoma therapeutics market size has grown strongly in recent years. It will grow from $8.3 billion in 2024 to $9.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to the rising incidence of breast cancer, increased adoption of combination therapies, growing prevalence of obesity and an aging population, expanded use of hormone receptor testing, and enhanced government support for cancer research.

The invasive ductal carcinoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $12.55 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the growing preference for personalized treatment strategies, increasing demand for minimally invasive surgical techniques, rising approvals of biosimilar monoclonal antibodies, expansion of the clinical pipeline for antibody-drug conjugates, and a stronger focus on value-based cancer care models. Key trends anticipated during the forecast period include the development of immune checkpoint inhibitors, integration of imaging and therapeutic systems, incorporation of digital health platforms into patient management, innovation in microRNA modulators, and advancements in nanoparticle-based drug delivery systems.

The increasing incidence of breast cancer is expected to drive the growth of the invasive ductal carcinoma therapeutics market in the coming years. Breast cancer is a condition in which cells within the breast multiply uncontrollably, forming a malignant tumor that can invade nearby tissues or metastasize to other parts of the body. The rise in breast cancer cases is largely attributed to lifestyle-related factors such as obesity and lack of physical activity, both of which elevate the risk of developing malignant tumors in breast tissue. Invasive ductal carcinoma therapeutics play a critical role in treating breast cancer by providing targeted and effective therapies specifically designed for the most common type of breast cancer. These treatments help limit tumor progression and spread through precision medicine, thereby enhancing patient outcomes and quality of life. For example, according to the American Cancer Society Facts and Figures, a U.S.-based nonprofit organization, the number of new breast cancer cases increased from 300,590 in 2023 to 313,510 in 2024. Thus, the rising incidence of breast cancer is contributing to the growth of the invasive ductal carcinoma therapeutics market.

Leading companies in the invasive ductal carcinoma (IDC) therapeutics market are concentrating on the development of innovative treatments, such as antibody-drug conjugates, to enhance the precision and effectiveness of targeted therapies while minimizing side effects. Antibody-drug conjugates (ADCs) are specialized cancer treatments that combine an antibody with a cytotoxic drug, allowing for the direct delivery of the drug to cancer cells while sparing healthy tissues. For example, in January 2024, AstraZeneca Pharma India Limited, an India-based pharmaceutical company, in partnership with Daiichi Sankyo Company, Limited, a Japan-based pharmaceutical firm, introduced trastuzumab deruxtecan. This antibody-drug conjugate is intended for adult patients with unresectable or metastatic HER2-positive breast cancer. It functions by directing a powerful topoisomerase I inhibitor (deruxtecan) to HER2-expressing cancer cells, leading to targeted DNA damage and subsequent cell death.

In December 2024, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to reinforce its position in the oncology sector by broadening its cancer drug portfolio, accelerating the advancement of innovative therapies, and supporting long-term growth in the cancer treatment market. Seagen Inc. is a U.S.-based biotechnology company focused on developing targeted therapies for invasive ductal carcinoma.

Major players in the invasive ductal carcinoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim, Mylan N.V., Daiichi Sankyo, Astellas Pharma Inc., Eisai Co. Ltd., BeiGene Ltd, Dr. Reddy’s Laboratories, Cipla Limited, Seagen Inc., Glenmark Pharmaceuticals, and Olema Pharmaceuticals Inc.

North America was the largest region in the invasive ductal carcinoma therapeutics market in 2024. The regions covered in invasive ductal carcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the invasive ductal carcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Invasive ductal carcinoma (IDC) therapeutics refers to the medical treatments used to manage and treat invasive ductal carcinoma, the most common form of breast cancer that originates in the milk ducts and spreads to the surrounding breast tissue. The primary goal of these treatments is to eliminate cancer cells, prevent further spread or recurrence, and enhance patient survival and quality of life. Treatment options typically include surgery, chemotherapy, and radiation therapy.

The main drug categories in invasive ductal carcinoma therapeutics are targeted therapy and hormone therapy. Targeted therapy involves treatments that specifically focus on cancer cells by identifying certain molecular markers or genetic characteristics of the tumor, minimizing damage to healthy cells. The different types of IDC include hormone receptor-positive, human epidermal growth factor receptor 2 positive (HER2+), and triple-negative breast cancer. These therapies are primarily utilized by hospitals, oncology clinics, and other healthcare providers.

The invasive ductal carcinoma therapeutics market research report is one of a series of new reports that provides invasive ductal carcinoma therapeutics market statistics, including the invasive ductal carcinoma therapeutics industry's global market size, regional shares, competitors with the invasive ductal carcinoma therapeutics market share, detailed invasive ductal carcinoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the invasive ductal carcinoma therapeutics market. This invasive ductal carcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The invasive ductal carcinoma therapeutics market consists of revenues earned by entities by providing services such as diagnostic imaging, biopsy procedures, hormone therapy, immunotherapy, and post-treatment monitoring and support care. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive ductal carcinoma therapeutics market also includes sales of diagnostic kits, biopsy tools, and medical devices used in surgical and radiation treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.